News|Articles|March 15, 2016
- Pharmaceutical Technology-03-15-2016
- Volume 2016 eBook
- Issue 1
Regulatory Considerations for Controlling Intermediates in Type-II Drug Master Files for the Manufacture of Generic Drug Substances
The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.
Advertisement
The authors present analysis of the state of control of intermediate identity and quality, based on analysis of recently submitted DMFs.
from Pharmaceutical Technology’s 2016 Solid Dosage Drug Development and Manufacturing eBook.
View other articles in the
Articles in this issue
almost 10 years ago
Optimizing Tablet Compressionalmost 10 years ago
Excipient Quality and Selectionalmost 10 years ago
Filling the Analysis Gap in the Move to Continuous Processingalmost 10 years ago
Modeling and Simulation Move Downstreamalmost 10 years ago
Unifying Excipient Databasesalmost 10 years ago
Establishing a New Performance Standard for HPMC CapsulesNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Industry Outlook 2026: Navigating AI, Sustainability, and Operational Resilience
2
Integrating AI and Machine Learning in Drug Discovery and Development
3
Single-Use Systems Enable Commercial-Scale CGT Manufacturing
4
EMA and FDA Collaborate on Framework for AI Use in Drug Development
5